Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience

Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Shalata, Walid, Zolnoorian, Jeremy, Migliozzi, Gabrielle, Jama, Ashraf Abu, Dudnik, Yulia, Cohen, Ahron Yehonatan, Meirovitz, Amichay, Yakobson, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056863/
https://www.ncbi.nlm.nih.gov/pubmed/36983011
http://dx.doi.org/10.3390/ijms24065938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056863/
https://www.ncbi.nlm.nih.gov/pubmed/36983011
http://dx.doi.org/10.3390/ijms24065938

Ejemplares similares